Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Gilead Sciences
NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more
NCT06846671 · CLL, Chronic Lymphocytic Leukemia
NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
NCT05294731 · B-cell Malignancy, Non-Hodgkin Lymphoma, and more
Clearview Cancer Institute
Huntsville, Alabama
UCLA Medical Center
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions